Back to Search Start Over

Highly immunosuppressive HLADR hi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma

Authors :
Huijuan Yang
Xuan Pei
Jingwen Wu
Liwei Qiu
Jiaqiang Ma
Saifullah Afridi
Yanan Chen
Shuang Ye
Jing Yu
Bin Lu
Xiaoming Zhang
Huihui Xu
Shyamal Goswami
Chunmei Cao
Teng Li
Libing Xiang
Source :
International Journal of Cancer. 146:1993-2006
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

Regulatory T cells (Tregs) are crucial for the maintenance of peripheral tolerance, but they also limit beneficial responses through cancer-induced immunoediting. The roles of Treg subsets in cervical squamous cell carcinoma (CSCC) are currently unknown. Here, we aimed to perform an extensive study with an increased resolution of the Treg compartment in the peripheral blood and tumor tissues of CSCC patients. We first identified that an HLADRhi Treg population in the peripheral blood was significantly increased in CSCC patients compared to precancer patients and healthy donors. We found that HLADRhi Tregs express high levels of a panel of inhibition and activation markers and the TCR-responsive transcription factors BATF and IRF4. However, this Treg subset showed reduced calcium influx after TCR crosslinking. In addition, HLADRhi Tregs are highly proliferative and vulnerable to apoptosis. Further studies demonstrated that the HLADRhi Tregs display high levels of suppressive activity. Quantitative multiplexed immunohistochemistry revealed that an increase in the number of tumor-infiltrating HLADRhi Tregs is associated with unfavorable classical risk parameters of advanced disease stage and stromal invasion. Context-based quantification revealed that a high frequency of stromal HLADRhi Tregs in patients is significantly associated with worse progression-free survival. In the current study, we characterized a population of highly activated and immunosuppressive HLADRhi Tregs in CSCC patients. An increased HLADRhi Treg frequency may be a potential biomarker to stratify CSCC patients and evaluate therapeutic efficacies in personalized immuno-oncology studies.

Details

ISSN :
10970215 and 00207136
Volume :
146
Database :
OpenAIRE
Journal :
International Journal of Cancer
Accession number :
edsair.doi...........fc4d7369a41bcdf1f29099a51aa099e0
Full Text :
https://doi.org/10.1002/ijc.32782